Latest ovarian cancer Stories

Connie K. Ho for redOrbit.com – Your Universe Online The U.S. Preventive Services Task Force recently issued a recommendation for adult women stating that routine screenings for ovarian cancer do not have any proven benefits and may actually have harmful effects. The Task Force is composed of national experts from preventive and evidence-based medicine who focus on providing recommendations on clinical preventive services. The recommendation, featured in Screening for Ovarian Cancer,...

In honor of National Ovarian Cancer Awareness Month, the Nurse Oncology Education Program (NOEP) encourages nurses to view its two free courses on the topic at http://www.noep.org. Every nurse can impact this disease through education, support, and advocacy. Austin, Texas (PRWEB) September 06, 2012 In honor of National Ovarian Cancer Awareness Month, the Nurse Oncology Education Program (NOEP) encourages nurses to view its two free courses on the topic at http://www.noep.org. Every nurse...

PARSIPPANY, N.J., Sept. 6, 2012 /PRNewswire/ -- In honor of National Ovarian Cancer Month and Gynecologic Cancer Month, both taking place in September, Walgreens and Ferring Pharmaceuticals Inc. today announced a collaboration to provide free access to certain fertility medications and educational resources as part of Ferring's h.e.a.r.t. BEAT program. The program is a patient assistance initiative funded by Ferring and provided as a public service to eligible women of reproductive...

ROCKVILLE, Md., Sept. 6, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today the publication of an article by Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, entitled "ENMD-2076, an Oral Inhibitor of Angiogenic and Proliferation Kinases, Has Activity in Recurrent, Platinum Resistant Ovarian Cancer," in the European Journal of Cancer. (Logo:...

BATON ROUGE, La., Aug. 28, 2012 /PRNewswire/ -- Esperance Pharmaceuticals today announced the completion of the run-in cohort of its Phase 2, randomized, multi?center trial of EP?100 in combination with paclitaxel for patients with advanced ovarian cancer. EP?100 is a targeted membrane?disrupting peptide (tMDP) designed to seek and destroy cancer cells that over?express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces. LHRH receptors are over?expressed in a...

PALO ALTO, Calif., Aug. 22, 2012 /PRNewswire-USNewswire/ -- Canary Foundation announces that it has received two contributions positioned to advance areas important to its mission to develop cancer early detection tests. The first is a gift for $7.5 million from the William K. Bowes Jr. Foundation to support a faculty position focused on clinical trials at the Canary Center at Stanford. The management of the clinical trial process is a growing need at the center with requirements...

New York City fertility clinic Center for Human Reproduction is initiating a new clinical trial to study testosterone supplementation as a treatment for poor ovarian reserve. New York, NY (PRWEB) August 20, 2012 Center for Human Reproduction (CHR), a leading fertility research and treatment center in New York City, has announced a new prospectively randomized controlled clinical trial to investigate the effects of testosterone supplementation in women with diminished ovarian reserve...

Proceeds help raise disease awareness and provide programs for ovarian cancer survivors. Philadelphia, PA (PRWEB) August 17, 2012 The Delaware Valley Chapter of the National Ovarian Cancer Coalition will hold its 14th Annual “Run/ Walk to Break the Silence on Ovarian Cancer” on Saturday, September 8, at Memorial Hall, Fairmount Park to raise awareness of ovarian cancer, celebrate ovarian cancer survivors, and remember those lost to the disease. All proceeds fund education and...

Proceeds help raise disease awareness and provide programs for ovarian cancer survivors. Pittsburgh, Pa (PRWEB) August 17, 2012 The Pittsburgh Chapter of the National Ovarian Cancer Coalition will hold its 12th Annual “Walk to Break the Silence on Ovarian Cancer” on Sunday, September 9, at the North Park Boathouse to raise awareness of ovarian cancer, celebrate ovarian cancer survivors, and remember those lost to the disease. All walk proceeds fund education and awareness as well as...

The presence of multiple ovarian cancer genomes in an individual patient and the absence or downregulation of the gene LRP1B are associated with the development of chemoresistance in women with the high-grade serous cancer subtype of ovarian cancer whose disease recurs after primary treatment. These study results are published in Cancer Research, a journal of the American Association for Cancer Research. David Bowtell, Ph.D., head of the Cancer Genomics and Genetic Program at the Peter...